Clinical Trial

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Study acronym: BAF_FRontier-1
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-11
minor Completion pushed: 2029-03 -> 2029-09 2026-05-14
Trial Details
NCT Number NCT07101328
Lead Sponsor Eli Lilly and Company
Conditions Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell
Enrollment 215 participants
Start Date 2026-05-28
Primary Completion 2027-04 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-10